Jingze Biotech Files for Hong Kong IPO for Third Time, With CICC and Guo Yuan as Joint Sponsors

According to Hong Kong Exchanges and Clearing (HKEX) disclosure on July 3, Jingze Biotech Pharmaceutical (Hefei) Co., Ltd. submitted its main board listing application to HKEX, with China International Capital Corporation (CICC) and Guo Yuan International as joint sponsors. The company, which focuses on assisted reproduction and ophthalmology pharmaceuticals, had previously filed for listing on June 27, 2025, and December 31, 2025.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments